US biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and lung scarring in patients who have serious cases of COVID-19 or who have ...

This study evaluated the potential of their wholly-owned asset LYT-100 (deupirfenidone) for use in treating idiopathic pulmonary fibrosis (IPF). Analysts from Leerink Partners, who maintain an ...